ESMO Congress | Conference

Nivolumab/Cabozantinib Combo Shows Promise in GU Cancers

October 18th 2016

Cabozantinib plus nivolumab demonstrated promising activity in the second-line setting and beyond at all dose levels tested in patients with advanced/refractory genitourinary cancers.

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

October 18th 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.

Dr. Hortobagyi on MONALEESA-2 Trial Results in HR+ Breast Cancer

October 18th 2016

Gabriel N. Hortobagyi, MD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses findings from the phase III MONALEESA-2 trial, which looked at the addition of the CDK 4/6 inhibitor ribociclib to endocrine therapy in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma

October 18th 2016

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.

Adding Bone Drugs to Radium-223 May Enhance Benefit in mCRPC

October 17th 2016

Men with bone-metastatic castration-resistant prostate cancer appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies, according to data from an extended-access program.

No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy

October 12th 2016

Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

October 11th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

October 11th 2016

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC

October 11th 2016

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study

October 11th 2016

First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.

Frontline Cabozantinib Bests Sunitinib in mRCC

October 11th 2016

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.

First-Line Pembrolizumab Shows Substantial Activity in Advanced Bladder Cancer

October 10th 2016

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.

Nivolumab Misses PFS Endpoint in First-Line Advanced NSCLC

October 10th 2016

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.

Unexpected Benefit Observed From Neoadjuvant Therapy in High-Risk Soft Tissue Sarcoma

October 10th 2016

A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy.

Adjuvant Sunitinib Extends DFS in High-Risk RCC

October 10th 2016

Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.

Atezolizumab Significantly Extends Survival in NSCLC

October 10th 2016

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC

October 9th 2016

Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

October 9th 2016

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

October 9th 2016

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.

Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

October 9th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.